• The Supplementary Medical Insurance (SMI) Trust Fund is adequately
financed into the indefinite future because, unlike the other trust funds,
its main financing sources -- enrolled beneficiary premiums and the
associated federal contributions from the Treasury -- are automatically
adjusted each year to cover costs for the upcoming year. Although the
financing is assured, the rapidly rising SMI costs have been placing
steadily increasing demands on beneficiaries and general taxpayers.
The projected long-term finances of the combined OASDI fund improved this year
primarily due to an upward revision to the level of labor productivity over the
projection period and a lower assumed long-term disability incidence rate. These
improvements were partially offset by a decrease in the assumed long-term total
fertility rate. The revision to labor productivity was based on stronger economic
growth in 2023 than had been anticipated in last year’s reports. The Trustees
lowered the long-term disability incidence and fertility rate assumptions based on
continued low levels in both series.
The projected long-term finances of the HI Trust Fund also improved this year
relative to last. This improvement was due to several factors, including a policy
change correcting for the way medical education expenses are accounted for in
Medicare Advantage rates starting in 2024, higher payroll tax income resulting
from the stronger-than-expected economy, and actual 2023 expenditures that were
lower than projected last year.
The change in the projected long-term finances of the SMI Trust Fund from last
year’s report varies over the projection period. For Part B, the long-range
projections as a percent of GDP are lower than those projected last year through
2056 and higher thereafter. This change reflects the combined effects of lower
projected spending for outpatient hospital and home health agency services and
revised GDP projections. For Part D, the expenditure share of GDP is projected to
be higher than last year early in the projection period and to continue to vary but
become more similar to last year’s estimates later in the projection period. These
changes largely reflect revisions to drug utilization, enrollment, and GDP
projections.
Lawmakers have many options for changes that would reduce or eliminate the
long-term financing shortfalls. Taking action sooner rather than later will allow
consideration of a broader range of solutions and provide more time to phase in
changes so that the public has adequate time to prepare.